remove_red_eye 492 Views
#Diabetes and Endocrinology #Internal Medicine #Pharmacist #Rheumatology
Sodium-glucose cotransporter-2 (SGLT2) inhibitors may reduce the risk for gout among adults with type 2 diabetes, new research suggests.
The study, involving more than 200,000 individuals from a US commercial insurance database, was published online January 13 in Annals of Internal Medicine. In this new study, there was a nearly 40% relative risk reduction in gout among adults prescribed SGLT2 inhibitors compared with those prescribed glucagon-like peptide-1 (GLP-1) receptor agonists, which do not decrease uric acid levels. The absolute risk reduction was about three fewer adults with gout per 1000 person-years.